Longtime KO client GOODLES, the brand that reimagined boxed mac and cheese, has officially closed its acquisition by the Barilla Group, an international, family-owned food company operating in more than 100 countries. Since GOODLES was founded in 2020, we’ve been proud to serve as the company’s legal counsel from formation…

KO client Synteric Robotics recently announced its launch and the successful close of its first pre-seed funding round. Synteric is developing inspection robots designed to access small, hard-to-reach, and potentially dangerous spaces. KO partner Jon Taylor and attorney Brooke Eckert represented Synteric in its formation and financing. Learn more.

KO client Watchmaker Genomics, a biotechnology company that specializes in advanced enzymology to develop precision tools for life sciences, recently announced that it has signed a long-term lease for about 100,000 square feet at Flatiron Park in Boulder. The new space will more than double the company’s manufacturing capacity.  KO…

For directors and officers, indemnification and advancement rights can be among the most important protections available when disputes arise from their service to a company. For companies, those same rights can create obligations that extend well beyond an executive’s or director’s departure. An August 12, 2026, final report by Magistrate…

California’s updated CCPA regulations, which became effective January 1, 2026, created a formal cybersecurity audit obligation for certain businesses whose processing of personal information presents “significant risk to consumers’ security.” This is the first of the generally applicable state privacy laws to mandate independent cybersecurity audits for certain businesses. This…

KO client PickNik, an industry recognized robotics software company and longtime steward of MoveIt, one of the world’s most widely adopted open-source robotics manipulation frameworks, recently announced that it has entered into an agreement to be acquired by Qualcomm Technologies, Inc. According to the announcement, this acquisition is intended to…

At KO Law, we’ve always believed that building a sustainable way to work is key to doing great work. As the firm has grown, we’ve stayed committed to that principle by creating a culture that values both excellence and life outside of work. One way we put that into practice…

KO client Kiora Pharmaceuticals, a clinical-stage biotechnology company focused on developing innovative therapies for ophthalmic diseases, recently announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD), one of South Korea’s leading pharmaceutical companies. KIO-301…